Crescent Biopharma, Inc.

NasdaqCM:CBIO Stock Report

Market Cap: US$502.1m

Crescent Biopharma Management

Management criteria checks 0/4

Crescent Biopharma's CEO is Josh Brumm, appointed in Mar 2025, has a tenure of 1.33 years. total yearly compensation is $13.26M, comprised of 4.2% salary and 95.8% bonuses, including company stock and options. directly owns 0.85% of the company’s shares, worth $4.25M. The average tenure of the management team and the board of directors is 1.3 years and 1.7 years respectively.

Key information

Josh Brumm

Chief executive officer

US$13.3m

Total compensation

CEO salary percentage4.18%
CEO tenure1.3yrs
CEO ownership0.8%
Management average tenure1.3yrs
Board average tenure1.7yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 29

Crescent Biopharma: Intriguing Developer Of ADC/PD1-VEGF Assets May Not Be Sufficiently Derisked

Summary Crescent Biopharma is developing CR-001, a PD-1 x VEGF bispecific antibody, aiming to rival Keytruda as an immuno-oncology backbone. I see Crescent's dual strategy—advancing CR-001 and building a best-in-class ADC portfolio—as a bold but high-risk approach in a competitive landscape. Despite promising mechanisms, near-term catalysts are limited, and clinical proof for CR-001, CR-002, and CR-003 remains lacking. I rate CBIO a Hold, preferring to wait for derisking clinical data before considering a more aggressive position. Read the full article on Seeking Alpha
Analysis Article • May 07

Rainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic

Shareholders in Crescent Biopharma, Inc. ( NASDAQ:CBIO ) may be thrilled to learn that the analysts have just delivered...

CEO Compensation Analysis

How has Josh Brumm's remuneration changed compared to Crescent Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$162m

Dec 31 2025US$13mUS$554k

-US$154m

Compensation vs Market: Josh's total compensation ($USD13.26M) is above average for companies of similar size in the US market ($USD2.40M).

Compensation vs Earnings: Insufficient data to compare Josh's compensation with company performance.

CEO

Josh Brumm (48 yo)

1.3yrs
Tenure
US$13,262,580
Compensation

Mr. Joshua T. Brumm, also known as Josh, is Chief Executive Officer & Director of Crescent Biopharma, Inc. from March 2025. He is Chairman of Amphista Therapeutics Limited. He is Director of AIRNA Corporat...

Leadership Team

NamePositionTenureCompensationOwnership
Joshua Brumm
CEO & Director1.3yrsUS$13.26m0.85%
$ 4.2m
Jonathan McNeill
President & COO1.3yrsUS$6.72m0.42%
$ 2.1m
Ellie Im
Chief Medical Officer1.3yrsUS$3.80m0.066%
$ 333.4k
Richard Scalzo
Chief Financial Officer1.3yrsno data0.061%
$ 306.7k
Ryan Lynch
Senior VP of Finance1.6yrsno data0.0092%
$ 45.9k
Wenjie Cheng
Senior Vice President of Technical Operations1.4yrsno datano data
Jan Pinkas
Chief Scientific Officer1yrno data0.067%
$ 336.0k
Barbara Hale
General Counsel & Corporate Secretary1.5yrsno data0.058%
$ 292.1k
Amy Reilly
Chief Communications Officer1.3yrsno datano data
Christopher Doughty
Chief Business Officer1.8yrsno data0.12%
$ 596.5k
Tanya Sengupta
Executive VP and Chief of Strategy & Operations1.3yrsno datano data
1.3yrs
Average Tenure
42yo
Average Age

Experienced Management: CBIO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Joshua Brumm
CEO & Director1.3yrsUS$13.26m0.85%
$ 4.2m
David Lubner
Independent Director1.3yrsUS$294.99k0%
$ 0
Jonathan Violin
Director1.8yrsUS$474.30k0.21%
$ 1.1m
Peter Harwin
Independent Chairman1.8yrsUS$151.58kno data
Alexandra Balcom
Independent Director1.7yrsUS$140.47k0%
$ 0
Susan Moran
Independent Director1.7yrsUS$136.96k0%
$ 0
1.7yrs
Average Tenure
49.5yo
Average Age

Experienced Board: CBIO's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 06:18
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Crescent Biopharma, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric SchmidtCantor Fitzgerald & Co.
Bradley CaninoGuggenheim Securities, LLC
Mitchell KapoorH.C. Wainwright & Co.